Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: TASK Applied Science
Company Location: Western America
Company Founding Year: 2016
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: South Africa
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Tuberculosis, Pulmonary
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05388448 |
TASK-009-SANF | P2 |
Completed |
Tuberculosis, Pulmonary |
2024-08-19 |
50% |
2025-02-22 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |